Holen Sie sich die Stockscreener-App
19.02
1.30%
-0.25
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
BNP Paribas Financial Markets Has $27,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics initiated with a Buy at BTIG - Yahoo Finance
BTIG Research Begins Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
BTIG initiates Buy rating on Cartesian Therapeutics stock highlighting mRNA CAR-T potential - Investing.com
Cartesian Therapeutics Announces New Employment Inducement Grants - Barchart
Cartesian Therapeutics Awards Key Talent with mRNA Cell Therapy Stock Options in Strategic Growth Move - StockTitan
Fmr LLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Fmr LLC Has $45.97 Million Stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics’ mRNA CAR-T Descartes-08 Produces Durable Responses in Myasthenia Gravis - CGTLive™
Cartesian Therapeutics (NASDAQ:RNAC) Earns “Buy” Rating from Needham & Company LLC - Defense World
Analysts Issue Forecasts for RNAC FY2024 Earnings - MarketBeat
Moving into Phase III, Cartesian data show momentum - The Pharma Letter
Cartesian Therapeutics Reports Promising Phase 2b Trial Results - Yahoo Finance
Cartesian Therapeutics (NASDAQ:RNAC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Cartesian Therapeutics Announces Positive Updated Results - GlobeNewswire
Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis Treatment - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.33 Consensus Price Target from Brokerages - Defense World
Great Point Partners LLC Invests $3.22 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.33 - MarketBeat
Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Cartesian therapeutics CTO sells $649,029 in stock By Investing.com - Investing.com Nigeria
Cartesian therapeutics CTO sells $649,029 in stock - Investing.com India
Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - The Manila Times
Cartesian Therapeutics to Present Key Phase 2b Trial Data for Myasthenia Gravis Treatment | RNAC Stock News - StockTitan
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St
Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat
Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million By Investing.com - Investing.com Nigeria
Cartesian Therapeutics executive sells $875,042 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada
Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Canada
Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com
Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com
Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com
Cartesian Therapeutics executive sells $875,042 in stock - Investing.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 - Yahoo Finance
Cartesian Therapeutics Reports Q3 2024 Financial Results - MSN
HC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00 - Defense World
Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World
Cartesian Therapeutics: Uncertainty Remains (NASDAQ:RNAC) - Seeking Alpha
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - MarketBeat
Cartesian Therapeutics Inc (RNAC) Reports Q3 2024 EPS of $(1.13), Revenue of $387K, Missing Analyst Estimates - GuruFocus.com
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics Awards New Employee Stock Options at $19.11 Per Share | RNAC | RNAC Stock News - StockTitan
Cartesian Therapeutics Inc. (RNAC) Quarterly 10-Q Report - Quartz
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):